|
PET and CT Scans in Patients With Locally Advanced Primary Rectal Cancer That Can Be Removed During Surgery Clinical Trials Information presented on Clinical Trials Search is not intended to be a substitute for qualified health advice, trips or treatment by using a genuine doctor. We aren't doctors. Always consult your mD on PET and CT Scans in Patients With Locally Advanced Primary Rectal Cancer That Can Be Removed During Surgery conditions. Clinical Trials Search.org is a site committed to listing clinical research studies in human subjects. PET and CT Scans in Patients With Locally Advanced Primary Rectal Cancer That Can Be Removed During Surgery Clinical research trials and PET and CT Scans in Patients With Locally Advanced Primary Rectal Cancer That Can Be Removed During Surgery health trials take place in a lot of of cities across the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / projects is to answer specific human medical questions. Clinical trials are a popular manner for physicians, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, like PET and CT Scans in Patients With Locally Advanced Primary Rectal Cancer That Can Be Removed During Surgery. PET and CT Scans in Patients With Locally Advanced Primary Rectal Cancer That Can Be Removed During Surgery Clinical Trials and other clinical trials allow for volunteers to have health treatment alternatives before they are available to the general public. Many times the test subjects obtain treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a PET and CT Scans in Patients With Locally Advanced Primary Rectal Cancer That Can Be Removed During Surgery clinical trial. Subjects oftentimes recieve the most effective healthcare possible for their PET and CT Scans in Patients With Locally Advanced Primary Rectal Cancer That Can Be Removed During Surgery condition. Hazards are a reality, however, and could include additional or frequent doctor visits, healthcare dangers (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with exacting guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "P" Clinical Trials Conditions > PET and CT Scans in Patients With Locally Advanced Primary Rectal Cancer That Can Be Removed During Surgery  PET and CT Scans in Patients With Locally Advanced Primary Rectal Cancer That Can Be Removed During Surgery
PET and CT Scans in Patients With Locally Advanced Primary Rectal Cancer That Can Be Removed During Surgery
For Condition: Stage 4 rectal cancer,stage 3 rectal cancer,stage 2 rectal cancer
Status: Recruiting
Sponsor(s): Memorial Sloan-Kettering Cancer Center , National Cancer Institute (NCI)
Synopsis: RATIONALE: Diagnostic procedures, such as PET and CT scans, may improve the ability to detect the extent of locally advancedprimary rectal cancer and may also help to measure a patient's response to treatment. PURPOSE: Diagnostic trial to study the effectiveness of PET and CT scans to detect residual or metastatic disease in patients who have locally advanced primary rectal cancer that can be removed during surgery.
Details: OBJECTIVES: - Determine if fludeoxyglucose F 18 positron emission tomography (FDG-PET) is superior to CT scan at monitoring rectal cancer response to radiation and chemotherapy by identifying residual rectal cancer in the rectal wall or pelvic lymph nodes in order to optimize selection of patients suitable for a sphincter preserving rectal cancer resection or a local excision. - Determine the accuracy of FDG-PET in detecting extrapelvic metastatic disease in primary rectal cancer patients considered operable on the basis of currently accepted diagnostic work-up, including abdominal CT scan and chest x-ray. OUTLINE: This is a diagnostic study conducted concurrently with multimodality management. Within 1-2 weeks prior to starting preoperative radiotherapy/chemotherapy, patients undergo baseline positron emission tomography (PET) imaging of the thorax, abdomen, and pelvis. Patients receive fludeoxyglucose F 18 (FDG) IV followed 45 minutes later by PET imaging. Patients also undergo baseline CT imaging of the abdomen and pelvis. A CT scan of the chest is obtained if the prestudy chest x-ray is abnormal. Patients receive preoperative radiotherapy/chemotherapy. Within 4-6 weeks of completion of radiotherapy/chemotherapy, patients undergo repeat FDG-PET imaging and CT scan. Patients undergo surgical resection 1-2 weeks later. PROJECTED ACCRUAL: A total of 125 patients will be accrued for this study within 3 years.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Primary resectable rectal cancer as determined by currently accepted diagnostic work-up, including CT scan and endorectal ultrasound (EUS) - Must meet criteria for preoperative radiotherapy and chemotherapy: - Bulky tumors and/or EUS evidence of T3-4 and/or N1 disease PATIENT CHARACTERISTICS: Age: - 18 and over Performance status: - Not specified Life expectancy: - Not specified Hematopoietic: - Not specified Hepatic: - Not specified Renal: - Not specified Other: - Not pregnant or nursing - No uncontrolled diabetes mellitus (i.e., greater than 175 mg/dL) - No intolerance of being inside PET scanner for duration of study - No vulnerable patients (e.g., mentally retarded or prisoners) PRIOR CONCURRENT THERAPY: Biologic therapy: - Not specified Chemotherapy: - See Disease Characteristics Endocrine therapy: - Not specified Radiotherapy: - See Disease Characteristics Surgery: - See Disease Characteristics
Total Enrollment:
Location and Contact Information:
Overall Study Official:
JoseGuillem, Study Chair, Memorial Sloan-Kettering Cancer Center
Memorial Sloan-Kettering Cancer Center *Recruiting*
New York City, New York, 10021
United States
Recruiting Jose Guillem 212-639-8278
Additional Information:
Study ID Numbers: CDR0000067567; MSKCC-99048,NCI-G00-1695
Study Start Date:
Record last reviewed: September 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00004891
Other Stage 2 Rectal Cancer Studies:
1. Combination Chemotherapy in Treating Patients With Recurrent or Metastatic Colorectal Cancer
2. FR901228 in Treating Patients With Advanced Colorectal Cancer That Has Progressed After a Previous Fluorouracil-Containing Regimen
3. Fluorouracil and Leucovorin With or Without Irinotecan in Treating Patients With Metastatic Colorectal Cancer
4. Chemotherapy With Raltitrexed and Fluorouracil in Treating Patients With Advanced Colorectal Cancer
5. Erlotinib in Treating Patients With Recurrent or Metastatic Colorectal Cancer
Related Studies:
Other stage 2 rectal cancer Clinical Trials
Other New York Clinical Trials
Other New York City Clinical Trials
PET and CT Scans in Patients With Locally Advanced Primary Rectal Cancer That Can Be Removed During Surgery
|
|
|
|
|
|
|
|
